Affiliation:
1. International Health Management Associates, Inc., Schaumburg, Illinois, USA
2. GlaxoSmithKline, Collegeville, Pennsylvania, USA
Abstract
ABSTRACT
Gepotidacin inhibits bacterial DNA replication through a mode different from that of fluoroquinolones. Gepotidacin and comparators were tested by broth and agar dilution against clinical isolates. The
in vitro
activities of gepotidacin were comparable against methicillin-susceptible and -resistant
Staphylococcus aureus
(MSSA and MRSA, respectively) isolates (MIC
90
, 0.5 μg/ml). The gepotidacin MIC
90
s were as follows (in micrograms per milliliter) for the indicated bacteria:
Streptococcus pyogenes
, 0.25;
Escherichia coli
, 2;
Moraxella catarrhalis
, ≤0.06;
Streptococcus pneumoniae
(0.25),
Haemophilus influenzae
, 1;
Clostridium perfringens
, 0.5; and
Shigella
spp., 1, including levofloxacin-resistant subsets. Gepotidacin warrants further investigation for clinical development.
Funder
DOD | Defense Threat Reduction Agency
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference12 articles.
1. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase
2. Fluoroquinolone-Gyrase-DNA Complexes
3. Type IIA topoisomerase inhibition by a new class of antibacterial agents
4. Bouchillon S, Hackel M, Miller LA, Scangarella-Oman NE. 2013. In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections, abstr F-1216. Abstr 53rd Intersci Conf Antimicrob Agents Chemother.
5. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed, M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
106 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献